000			01928 a2200529 4500
005			20250516091315.0
264		0	_c20120905
008			201209s 0 0 eng d
022			_a2046-4924
024	7		_a10.3310/hta16220 _2doi
040			_aNLM _beng _cNLM
100	1		_aRogers, G
245	0	0	_aDasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. _h[electronic resource]
260			_bHealth technology assessment (Winchester, England) _c2012
300			_a1-410 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
650	0	4	_aBenzamides
650	0	4	_aBlast Crisis _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aCost-Benefit Analysis
650	0	4	_aDasatinib
650	0	4	_aDecision Support Techniques
650	0	4	_aDisease Progression
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aHealth Care Costs _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aIncidence
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy
650	0	4	_aLeukemia, Myeloid, Accelerated Phase _xdrug therapy
650	0	4	_aLeukemia, Myeloid, Chronic-Phase _xdrug therapy
650	0	4	_aModels, Economic
650	0	4	_aPiperazines _xpharmacology
650	0	4	_aPrognosis
650	0	4	_aProtein Kinase Inhibitors _xeconomics
650	0	4	_aPyrimidines _xeconomics
650	0	4	_aQuality of Life
650	0	4	_aThiazoles _xeconomics
700	1		_aHoyle, M
700	1		_aThompson Coon, J
700	1		_aMoxham, T
700	1		_aLiu, Z
700	1		_aPitt, M
700	1		_aStein, K
773	0		_tHealth technology assessment (Winchester, England) _gvol. 16 _gno. 22 _gp. 1-410
856	4	0	_uhttps://doi.org/10.3310/hta16220 _zAvailable from publisher's website
999			_c21748818 _d21748818